Javascript on your browser is not enabled.

Advertisement

Brinton Pharmaceuticals Receive $8 Billion Series B Funding From India Alternatives

This transaction marks the second investment in Brinton by an institutional investor, following Tata Capital Healthcare Fund’s investment in 2017.

Photo Credit : Shutterstock,

India Alternatives Investment Advisors invested up to $8 million for a significant minority stake in Brinton Pharmaceuticals Limited. Among the fastest growing companies in the Indian pharmaceutical market, Brinton is focused on dermatology and has recently expanded into the paediatric dermatology & respiratory segments. Equirus Capital Private Limited acted as an exclusive financial advisor to Brinton Pharmaceuticals on this transaction.

Speaking on the occasion, Mr. Rahulkumar Darda, Chairman & Managing Director, Brinton Pharmaceuticals said, “We are excited to partner with an investor of the calibre of India Alternatives and strongly believe this association will bring synergies and help us continue our profitable growth journey. This investment will enhance our capabilities in formulations and Research & Development for niche areas of dermatology and cosmetology and support expansion of the company’s footprint within India as well as globally.”

This transaction marks the second investment in Brinton by an institutional investor, following Tata Capital Healthcare Fund’s investment in 2017.   

Vijey Christopher J, Director, Brinton Pharmaceuticals added, “In a short span of time Brinton has made its presence felt both in dermatology and paediatrics through our innovative high quality products stemming from world-class R&D units across the globe. We are aiming for a leadership position in our represented product markets and have a strategic road-map to achieve several milestones in the coming years.”        

Commenting on the investment, Shivani Bhasin Sachdeva, Founder & CEO, India Alternatives said, “India Alternatives’ investment in Brinton reflects its recognition of the Company’s solid management team, differentiated brands and focus on niche therapeutic segments. The investment in Brinton fits very well with two of our themes of women oriented consumption and health & wellness. We are excited to partner with Rahul and his team to support them through the next leg of their journey.”

On the successful closure of the transaction, Ajay Garg, Managing Director, Equirus Capital commented, “This transaction is testament to Brinton’s sound leadership and the significant potential of the Company’s varied brand portfolio. We believe this partnership with India Alternatives will help the company scale even greater heights.”


Tags assigned to this article:
funding

Around The World

Advertisement